| Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer M Gauthé, M Richard-Molard, J Fayard, JL Alberini, W Cacheux, A Lièvre European journal of nuclear medicine and molecular imaging 44, 63-70, 2017 | 52 | 2017 |
| 68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of … A Fourquet, C Aveline, O Cussenot, G Créhange, F Montravers, JN Talbot, ... Scientific Reports 10 (1), 2104, 2020 | 38 | 2020 |
| Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers M Gauthé, M Richard-Molard, W Cacheux, P Michel, JL Jouve, E Mitry, ... Digestive and Liver Disease 47 (6), 443-454, 2015 | 38* | 2015 |
| Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours M Paquet, M Gauthé, J Zhang Yin, V Nataf, O Bélissant, P Orcel, C Roux, ... European Journal of Nuclear Medicine and Molecular Imaging 45, 1710-1720, 2018 | 36 | 2018 |
| French AFU Cancer Committee Guidelines-Update 2022-2024: prostate cancer-Diagnosis and management of localised disease G Ploussard, G Fiard, E Barret, L Brureau, G Créhange, C Dariane, ... Progrès en Urologie 32 (15), 1275-1372, 2022 | 32 | 2022 |
| PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive M Gauthé, O Belissant, A Girard, J Ohnona, AS Cottereau, V Nataf, ... Progres en Urologie: Journal de L'association Francaise D'urologie et de la …, 2017 | 26* | 2017 |
| Biomarker in active surveillance for prostate cancer: a systematic review C Manceau, G Fromont, JB Beauval, E Barret, L Brureau, G Créhange, ... Cancers 13 (17), 4251, 2021 | 25 | 2021 |
| Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study P Olivier, AL Giraudet, A Skanjeti, C Merlin, P Weinmann, I Rudolph, ... Journal of Nuclear Medicine 64 (4), 579-585, 2023 | 23 | 2023 |
| 18F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism M Gauthé, A Dierick-Gallet, T Delbot, L Bricaire, J Bertherat, MO North, ... World Journal of Surgery 44, 3761-3769, 2020 | 22 | 2020 |
| Thyroid incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT revealing a medullary thyroid carcinoma R Ciappuccini, A Edet-Sanson, V Saguet-Rysanek, M Gauthé, S Bardet Clinical Nuclear Medicine 44 (8), 663-665, 2019 | 22 | 2019 |
| Overview of the development and use of Akt inhibitors in prostate cancer A Gasmi, G Roubaud, C Dariane, E Barret, JB Beauval, L Brureau, ... Journal of Clinical Medicine 11 (1), 160, 2021 | 21 | 2021 |
| Restaging the Biochemical Recurrence of Prostate Cancer with [68Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management A Fourquet, L Lahmi, T Rusu, Y Belkacemi, G Créhange, A de La Taille, ... Cancers 13 (7), 1594, 2021 | 19 | 2021 |
| Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer … YM Chevalme, L Boudali, M Gauthé, C Rousseau, A Skanjeti, C Merlin, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 2935-2950, 2021 | 18 | 2021 |
| Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis C Dariane, G Ploussard, E Barret, JB Beauval, L Brureau, G Créhange, ... World Journal of Urology 41 (3), 641-651, 2023 | 15 | 2023 |
| Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic) G Ploussard, A Grabia, E Barret, JB Beauval, L Brureau, G Créhange, ... World Journal of Urology, 1-7, 2022 | 13 | 2022 |
| Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. J Ohnona, V Nataf, M Gauthe, S Balogova, O Belissant Benesty, ... Neoplasma 66 (1), 2019 | 13 | 2019 |
| Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer … M Gauthé, C Aveline, F Lecouvet, L Michaud, C Rousseau, M Tassart, ... World Journal of Urology 37, 1587-1595, 2019 | 12 | 2019 |
| Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate … M Gauthé, K Zarca, C Aveline, F Lecouvet, S Balogova, O Cussenot, ... BMC medical imaging 20, 1-13, 2020 | 11 | 2020 |
| Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis? M Gauthé, N Testart Dardel, F Ruiz Santiago, J Ohnona, V Nataf, ... European Radiology 28, 3943-3952, 2018 | 11 | 2018 |
| Pituitary adenoma recurrence suspected on central hyperthyroidism despite empty sella and confirmed by 68Ga-DOTA-TOC PET/CT M Gauthé, J Sarfati, N Bourcigaux, S Christin-Maitre, JN Talbot, ... Clinical Nuclear Medicine 42 (6), 454-455, 2017 | 11 | 2017 |
olivier cussenotProfesseur médecine Sorbonne Université Paris France在 sorbonne-universite.fr 的电子邮件经过验证
